Edwards Lifesciences (EW)
71.38
-0.01 (-0.01%)
Edwards Lifesciences is a global leader in innovative medical technology, specializing in heart valve repair and replacement, as well as critical care monitoring
The company focuses on developing advanced products to enhance the quality of heart surgery and improve patient outcomes. Edwards Lifesciences is dedicated to addressing cardiovascular disease, which remains a leading cause of death worldwide, by providing solutions that enable less invasive procedures and better management of patients with heart-related conditions. Through continuous research and development, the company strives to transform patient care in the fields of heart disease and surgical intervention.

Edwards Lifesciences Corporation (NYSEEW) today announced it will participate in the TD Cowen 45th Annual Health Care Conference on Tuesday, Mar. 4, 2025.
By Edwards Lifesciences Corporation · Via Business Wire · February 25, 2025

Edwards Lifesciences (NYSEEW) today reported financial results for the quarter and full-year ended Dec. 31, 2024.
By Edwards Lifesciences Corporation · Via Business Wire · February 11, 2025

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Edwards Lifesciences Corporation (“the Company”) (NYSEEW).
By Kahn Swick & Foti, LLC · Via Business Wire · February 7, 2025

Edwards Lifesciences (NYSEEW) plans to announce its operating results for the quarter ended December 31, 2024 after the market closes on Tuesday February 11, 2025, and will host a conference call at 5:00 p.m. ET that day to discuss those results.
By Edwards Lifesciences Corporation · Via Business Wire · February 4, 2025

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Edwards Lifesciences Corporation (“the Company”) (NYSEEW).
By Kahn Swick & Foti, LLC · Via Business Wire · January 24, 2025

Edwards Lifesciences Corporation (NYSEEW) today announced it will participate in the J.P. Morgan Healthcare Conference on Tuesday, Jan. 14, 2025.
By Edwards Lifesciences Corporation · Via Business Wire · January 7, 2025

NEW YORK, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Edwards Lifesciences Corp (NYSEEW) on behalf of long-term stockholders following a class action complaint that was filed against Edwards on October 14, 2024 with a Class Period from February 6, 2024 to July 24, 2024. Our investigation concerns whether the board of directors of Edwards have breached their fiduciary duties to the company.
By Bragar Eagel & Squire · Via GlobeNewswire · December 17, 2024

NEW YORK, NY / ACCESSWIRE / December 13, 2024 / If you suffered a loss on your Edwards Lifesciences Corporation (NYSEEW) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:
Via ACCESSWIRE · December 13, 2024

NEW YORK, NY / ACCESSWIRE / December 13, 2024 / If you suffered a loss on your Edwards Lifesciences Corporation (NYSEEW) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:
Via ACCESSWIRE · December 13, 2024

NEW YORK, NY / ACCESSWIRE / December 13, 2024 / If you suffered a loss on your Edwards Lifesciences Corporation (NYSEEW) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:
Via ACCESSWIRE · December 13, 2024

NEW YORK, NY / ACCESSWIRE / December 13, 2024 / If you suffered a loss on your Edwards Lifesciences Corporation (NYSEEW) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:
Via ACCESSWIRE · December 13, 2024

NEW YORK, NY / ACCESSWIRE / December 13, 2024 / If you suffered a loss on your Edwards Lifesciences Corporation (NYSEEW) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:
Via ACCESSWIRE · December 13, 2024

NEW YORK, NY / ACCESSWIRE / December 13, 2024 / If you suffered a loss on your Edwards Lifesciences Corporation (NYSEEW) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:
Via ACCESSWIRE · December 13, 2024

NEW YORK, NY / ACCESSWIRE / December 12, 2024 / If you suffered a loss on your Edwards Lifesciences Corporation (NYSEEW) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:
Via ACCESSWIRE · December 12, 2024

NEW YORK, NY / ACCESSWIRE / December 12, 2024 / If you suffered a loss on your Edwards Lifesciences Corporation (NYSEEW) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:
Via ACCESSWIRE · December 12, 2024

NEW YORK, NY / ACCESSWIRE / December 12, 2024 / If you suffered a loss on your Edwards Lifesciences Corporation (NYSEEW) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:
Via ACCESSWIRE · December 12, 2024

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Edwards Lifesciences Corporation (“Edwards” or the “Company”) (NYSEEW) and reminds investors of the December 13, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
By Faruqi & Faruqi, LLP · Via Business Wire · December 12, 2024

The Law Offices of Frank R. Cruz reminds investors of the upcoming December 13, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Edwards Lifesciences Corporation (“Edwards Lifesciences” or the “Company”) (NYSEEW) securities between February 6, 2024 and July 24, 2024, inclusive (the “Class Period”).
By The Law Offices of Frank R. Cruz · Via Business Wire · December 12, 2024

NEW YORK, NY / ACCESSWIRE / December 12, 2024 / If you suffered a loss on your Edwards Lifesciences Corporation (NYSEEW) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:
Via ACCESSWIRE · December 12, 2024

NEW YORK, NY / ACCESSWIRE / December 12, 2024 / If you suffered a loss on your Edwards Lifesciences Corporation (NYSEEW) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:
Via ACCESSWIRE · December 12, 2024

RADNOR, PA / ACCESSWIRE / December 12, 2024 / The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Edwards Lifesciences Corporation ("Edwards") (NYSEEW) on behalf of investors who purchased or otherwise acquired Edwards securities between February 6, 2024 and July 24, 2024, inclusive (the "Class Period") The lead plaintiff deadline is December 13, 2024.
Via ACCESSWIRE · December 12, 2024

Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of all purchasers of securities of Edwards Lifesciences Corporation (NYSEEW) between February 6, 2024 and July 24, 2024. Edwards describes itself as an “international company that researches, develops, provides products and technologies for heart valve repair and replacement therapies, as well as critical care monitoring solutions.”
By Rosen Law Firm · Via Business Wire · December 11, 2024

NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Edwards Lifesciences Corp (“Edwards” or the “Company”) (NYSEEW) in the United States District Court for the Central District of California on behalf of all persons and entities who purchased or otherwise acquired Edwards securities between February 6, 2024 and July 24, 2024, both dates inclusive (the “Class Period”). Investors have until December 13 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
By Bragar Eagel & Squire · Via GlobeNewswire · December 10, 2024

NEW YORK, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:
By Bernstein Liebhard LLP · Via GlobeNewswire · December 9, 2024

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · December 9, 2024